Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074

Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors

Moosa Mohammadi, Gerald McMahon, Li Sun et al. · Science · 1997 · 1.1K citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas

David Cappellen, Catherine De Oliveira, David Ricol et al. · Nature Genetics · 1999 · 705 citations

Medicine, Molecular Genetics, Oncology +14

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

Marta Chesi, Elena Nardini, Leslie A. Brents et al. · Nature Genetics · 1997 · 647 citations

Medicine, Molecular Genetics, Oncology +13

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Alexander Laird, Peter Vajkoczy, Laura K. Shawver et al. · PubMed · 2000 · 497 citations

Medicine, Medicinal Chemistry, Pharmacology +16

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression

Jonathan J. Keats, Tony Reiman, Christopher A. Maxwell et al. · Blood · 2003 · 384 citations

Medicine, Hematology, Oncology +7